Navigation Links
Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel
Date:11/20/2007

PRINCETON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc. (Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services, today announced the appointment of William J. Thomas, Esq. as Vice President and General Counsel.

Mr. Thomas was formerly Senior Vice President and General Counsel for Cytogen Corporation responsible for all legal matters including the management of outside general and intellectual property counsel. Prior to joining Cytogen, Mr. Thomas was a senior partner with the law firm of Wilmer Cutler Pickering Hale and Dorr LLP. Previously, he was a partner at the law firm Buchanan Ingersoll P.C. Mr. Thomas has more than 20 years of experience in the areas of general corporate issues, mergers and acquisitions, securities law compliance and managing intellectual property. Mr. Thomas received a J.D. degree from Fordham University School of Law and a B.A. degree in Political Science from Rutgers University.

Thomas A. Bologna, President and Chief Executive Officer of Orchid said, "I am pleased that Bill is joining Orchid's management team. He is a proactive and business oriented General Counsel with the legal experience and skill set that we believe will complement our management team well."

About Orchid Cellmark

Orchid Cellmark Inc. is a leading international provider of DNA testing services for human identity testing and agricultural applications. In the human identity area, Orchid Cellmark provides DNA testing services for forensic investigation, paternity testing and family relationship analysis and security applications. In the agriculture field, Orchid Cellmark provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these segments reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise and the world-renowned Cellmark brand that has been associated with exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at http://www.orchid.com.

All statements in this press release that are not historical are forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995., including but not limited to Orchid Cellmark's belief that Mr. Thomas has the legal experience and skill set that will complement its management team well. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, Orchid Cellmark's ability to timely and successfully integrate ReliaGene's business, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark's products and services, dependence on government funding and collaborations, regulatory approvals, competition, intellectual property of others, patent protection, litigation, the timing of release of federal funds, the timing and amount of contracts put up for bid, Orchid Cellmark's ability to timely and successfully initiate operational efficiencies, lower overhead and other remedial measures and Orchid Cellmark's continued relationship with DEFRA. These risks and other additional factors affecting these statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.

Contacts

Investors: Media:

Mary Bashore Barbara Lindheim

Orchid Cellmark Inc. GendeLLindheim BioCom Partners

(609) 750-2324 (212) 918-4650


'/>"/>
SOURCE Orchid Cellmark Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Orchid Cellmark Reports Third Quarter 2007 Financial Results
2. WorldHeart Appoints David Pellone Chief Financial Officer
3. Novo Nordisk Appoints New Leader of North American Business
4. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
5. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
6. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
7. Resonant Medical Appoints New Vice President of Global Sales
8. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
9. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
10. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
11. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... London, CT (PRWEB) , ... June 27, 2017 ... ... the Alice P. Fabrykiewicz Scholarship Foundation Fundraiser hygiene symposium in Mystic, CT. Covering ... Toback and Urbanski offered their experience in these popular periodontal procedures. Drs. Toback ...
(Date:6/27/2017)... Valley, CA (PRWEB) , ... June 27, 2017 , ... ... since 2001 suffer from PTSD. Yet less than 20% will receive adequate care due ... those with PTSD won't receive any care at all. And left untreated, veterans are ...
(Date:6/27/2017)... ... ... Children’s National Health System received top honors in the 2017-18 U.S News ... out of more than 1500 neonatal intensive care units coast to coast. ... to the top performing children’s hospitals in the country. , In addition to ...
(Date:6/26/2017)... ... 26, 2017 , ... Dr. Martin Bastuba, MD, FACS, founder ... the Fertility Center of California, is pleased to announce the addition of two ... TESA (percutaneous testicular sperm extraction). These minimally invasive treatments are primarily used to ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... leakage is revolutionizing the way women look and feel about themselves and their ... of female sexual dysfunction and urinary leakage head on with a ground breaking ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... May 26, 2017  Endo International plc (NASDAQ: ... and CEO, will represent the Company in a fireside chat ... on Tuesday, June 13, 2017 at 10:40 a.m. PT / ... Resort in Rancho Palos Verdes, CA. ... event will be available on the Company,s website at ...
(Date:5/24/2017)... May 24, 2017  ivWatch LLC today announced ... (OEM) Board to enable seamless integration of ivWatch,s ... systems, infusion pumps and other devices. By integrating ... able to help health care customers deliver a ... related to IV therapy. "The ivWatch ...
(Date:5/22/2017)... COTTAGE, N.Y. , May 22, 2017 /PRNewswire/ ... antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of a ... plain English, the results of a clinical study ... one year treatment with Gene-Eden-VIR/Novirin in individuals suffering ... important to note that there are no other ...
Breaking Medicine Technology: